Although we identified low activity of capivasertib in PTEN-mutant cancers when used as a single agent, AKT inhibition in combination with paclitaxel chemotherapy might be efficacious in PTEN-mutant cancers.22, 23 Capivasertib plus fulvestrant might be efficacious in endocrine-resistant oestrogen receptor-positive breast cancer without mutation selection, as shown in the FAKTION trial.24 The gene discussed is AKT1; the disease is breast cancer.